379228-58-7

Basic information

• Product Name: 5,7-DIFLUOROQUINAZOLIN-4(3H)-ONE
• Synonyms: 5,7-Difluoro-3,4-dihydroquinazolin-4-one;4(3H)-Quinazolinone, 5,7-difluoro-;5,7-difluoroquinazolin-4(1H)-one;5,7-Difluoro-1H-quinazolin-4-one;5,7-Difluoroquinazolin-4(3H);5,7-Difluoro-4(3H)-quinazolinone;5,7-DIFLUOROQUINAZOLIN-4(3H)-ONE
• CAS NO: 379228-58-7
• Molecular Formula: C₈H₄F₂N₂O
• Molecular Weight: 182.13
• Mol File: 379228-58-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 297.336°C at 760 mmHg
• Flash Point: 133.625°C
• Appearance: /
• Density: 1.55
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.62
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -1.20±0.20(Predicted)
• CAS DataBase Reference: 5,7-DIFLUOROQUINAZOLIN-4(3H)-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 5,7-DIFLUOROQUINAZOLIN-4(3H)-ONE(379228-58-7)
• EPA Substance Registry System: 5,7-DIFLUOROQUINAZOLIN-4(3H)-ONE(379228-58-7)

Safety Data

• Hazardous Substances Data: 379228-58-7(Hazardous Substances Data)

Usage

Description

5,7-Difluoroquinazolin-4(3H)-one is an organic compound belonging to the quinazolinone family. It is characterized by the presence of two fluorine atoms at the 5th and 7th positions of the quinazolinone structure. 5,7-DIFLUOROQUINAZOLIN-4(3H)-ONE is known for its potential applications in the pharmaceutical industry, particularly as a key intermediate in the synthesis of various bioactive molecules.

Uses

Used in Pharmaceutical Industry:
5,7-Difluoroquinazolin-4(3H)-one is used as a key intermediate in the process development and scale-up of an efficient route for the manufacturing of SRC kinase inhibitor AZD0530. 5,7-DIFLUOROQUINAZOLIN-4(3H)-ONE plays a crucial role in the synthesis of AZD0530, which is a potent inhibitor of SRC kinase, a protein involved in various cellular processes, including cell proliferation, survival, and migration. By inhibiting SRC kinase, AZD0530 has the potential to exhibit anti-cancer properties and be used in the treatment of various types of cancer.

InChI:InChI=1/C8H4F2N2O/c9-4-1-5(10)7-6(2-4)11-3-12-8(7)13/h1-3H,(H,11,12,13)

Upstream product

• 893428-66-5 2-amino-4,6-difluoro-benzamide 
• 122-51-0 orthoformic acid triethyl ester 
• 290-87-9 1,3,5-Triazine 
• 126674-77-9 2-amino-4,6-difluorobenzoic acid 
• 126674-93-9 4,6-difluoro-1H-indole-2,3-dione 
• 372-39-4 3,5-difluoroaniline 
• 379228-57-6 methyl 2-amino-4,6-difluorobenzoate 
• 3473-63-0 formamidine acetic acid 

Downstream Products

• 692059-53-3 4-chloro-7-(2, 4-dimethoxybenzyloxy)-5 isopropoxyquinazoline 
• 719304-92-4 4-(5-chloro-2-methoxypyridin-4-ylamino)-7-(2, 4-dimethoxybenzyloxy) - 5-isopropoxyquinazoline 
• 768360-27-6 (2-chloro-5-methoxy-pyridin-3-yl)-[7-(2,4-dimethoxy-benzyloxy)-5-isopropoxy-quinazolin-4-yl]-amine 
• 379228-59-8 7-fluoro-5-((tetrahydro-2H-pyran-4-yl)oxy)quinazoline-4(3H)-one 
• 791602-75-0 4-chloro-5,7-difluoroquinazoline 
• 379228-27-0 5,7-dimethoxyquinazolin-4(3H)-one 
• 379228-33-8 5,7-bis(benzyloxy)quinazolin-4(3H)-one 
• 893428-67-6 C₂₀H₂₈N₄O₄ 

Relevant articles and documents

Process research and development for the kilogram manufacture of the SRC kinase inhibitor AZD0530

Process research and development of a synthetic route towards a novel SRC kinase inhibitor is described. The Medicinal Chemistry route was very long and suffered from extensive use of chlorinated solvents and chromatography. A number of steps in the Medic

CHEMICAL PROCESS

The present invention relates to chemical processes useful in the manufacture of the compound 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]- 5-tetrahydropyran-4-yloxyquinazoline (the active entity within AZD0530), to intermed